# An Open-Label Extension Study to Evaluate the Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Patients 16 Years and Older With Partial Onset Seizures.

> **NCT00991757** · PHASE3 · COMPLETED · sponsor: **SK Life Science, Inc.** · enrollment: 991 (actual)

## Conditions studied

- Epilepsy
- Complex Partial Seizures
- Epilepsy, Complex Partial
- Epilepsies, Partial

## Interventions

- **DRUG:** carisbamate

## Key facts

- **NCT ID:** NCT00991757
- **Lead sponsor:** SK Life Science, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 991 (ACTUAL)
- **Last updated:** 2013-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00991757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00991757, "An Open-Label Extension Study to Evaluate the Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Patients 16 Years and Older With Partial Onset Seizures.". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00991757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*